// App-Quantinova.ai

[AB0422] : IMPACT OF COMBINATION ETANERCEPT-DMARD INDUCTION THERAPY IN ACTIVE RHEUMATOID ARTHRITIS: INTERIM RESULTS OF AN INTERNATIONAL TREAT-TO-TARGET STUDY CONDUCTED IN REGIONS WITH LIMITED BIOLOGIC ACCESS

Researchers

Presenter

  • K. Pavelka

Principal Investigators

  • N. Akkoc

  • M. Al-Maini

  • E. Mahgoub

  • B. Vlahos

  • C.A. Zerbini

  • C. Bao

  • D.E. Karateev

  • E.L. Nasonov

  • R. Pedersen

  • A. Dinh

  • Q. Shen

  • R. Vasilescu

Medical Centers

  • Charles Univ and VFN, Prague, Czech Republic

  • Shanghai Renji Hospital, Shanghai, China

  • Ege University School of Medicine, Izmir, Turkey

  • Al Noor Hospital, Abu Dhabi, United Arab Emirates

  • Centro Paulista de Investigacoe s Clinicas, Sao Paulo, Brazil

Locations

  • Brazil

  • Czech Republic

  • China

  • Turkey

  • United Arab Emirates

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • HWA-486

  • Etanercept

  • CHS-0214

  • Prednisone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved